SenesTech, a company specializing in the development and commercialization of fertility control products, reported a net loss of $4.9 million for the nine months ended September 30, 2024, with a net loss of $1.5 million for the third quarter of the same year. Despite the losses, the company saw a 51% increase in revenue year-over-year for the nine-month period, reaching $1.356 million, driven by the launch of their latest Evolve product offerings. The company's gross profit margin improved to 51.5% for the nine months ended September 30, 2024, compared to 45.6% for the same period in 2023. Research and development expenses increased slightly, while selling, general, and administrative expenses decreased due to lower personnel-related expenses and professional fees. SenesTech continues to focus on the commercialization of...Show More

SenesTech, a company specializing in the development and commercialization of fertility control products, reported a net loss of $4.9 million for the nine months ended September 30, 2024, with a net loss of $1.5 million for the third quarter of the same year. Despite the losses, the company saw a 51% increase in revenue year-over-year for the nine-month period, reaching $1.356 million, driven by the launch of their latest Evolve product offerings. The company's gross profit margin improved to 51.5% for the nine months ended September 30, 2024, compared to 45.6% for the same period in 2023. Research and development expenses increased slightly, while selling, general, and administrative expenses decreased due to lower personnel-related expenses and professional fees. SenesTech continues to focus on the commercialization of its fertility control products in the United States and internationally, with the expectation that cash and cash equivalents, along with anticipated revenue and potential equity sales, will fund operations for at least the next four months. However, the company acknowledges the need for additional financing to achieve profitability and may need to raise capital through equity or debt financing to support ongoing commercialization and development efforts.